JLE

Epileptic Disorders

MENU

End of the barbexaclone era: an experience of treatment withdrawal Volume 15, issue 3, September 2013

Borromei A, Caramelli R, Cipriani G, Giancola LC, Guerra L, Lozito A. Neurotraumatology and post-traumatic epilepsy. Prevention, treatment and long-term follow-up. Barbexaclone + phenobarbital (maliasin) versus diphenylhydantoin, phenobarbital, primidone, carbamazepin. Minerva Med 1987; 78: 1687-705.

Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia 2012 ; 53 : 40-46.

Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as ınitialmonotherapy for epileptic seizures and syndromes. Epilepsia 2006 ; 47 : 1094-1120.

Iven H, Feldbusch E. Pharmacokinetics of phenobarbital and propylhexedrine after administration of barbeksaklon in the mouse. Naunyn Schmiedebergs Arch Pharmacol 1983 ; 324 : 153-159.

Ommaty R. Barbexaclone. Vademecum. 32nd ed. Ankara: Matsa Edition, 2009; 851-852.

Perucca E, Grimaldi R, Ruberto G, Gelmi C, Trimarchi F, Crema A. Comparative kinetics of phenobarbital after administration of the acid and the propylhexedrine salt (barbexaclone). Eur J Clin Pharmacol 1986 ; 29 : 729-730.

Visintini D, Calzetti S, Mancia D. Barbeksaklon in the treatment of the epilepsies (author's transl). Riv Patol Nerv Ment 1981 ; 102 : 29-37.